Global Clinical Diagnostics Market Size & Analysis
20 mars 2023 12h11 HE
|
Global Market Estimates
Brooklyn, New York, March 20, 2023 (GLOBE NEWSWIRE) -- According to a recently revamped/updated market research report published by Global Market Estimates, the Global Clinical Diagnostics Market is...
IMAC Holdings and Brain Scientific Announce a Strategic Merger to Create Synergistic End-To-End Neurological Solution
20 mars 2023 06h30 HE
|
Brain Scientific Inc.
BRENTWOOD, Tenn. and LAKEWOOD RANCH, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IMAC Holdings, Inc. (“IMAC”) (Nasdaq: BACK), a regenerative rehabilitation company focused on...
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
15 mars 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
08 mars 2023 03h01 HE
|
Mainz BioMed NV
Sponsor of Gastro Update 2023, 2-day scientific and training events for gastroenterology professionals Patient Education Day in the City of Mainz, Germany, where the Company is headquartered ...
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
01 mars 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 01, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
28 févr. 2023 08h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that...
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
21 févr. 2023 03h01 HE
|
Mainz BioMed NV
Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY...
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
15 févr. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
The Global Hematology Diagnostics Market Revenue totaled USD 780 million in 2023 and is expected to reach USD 2 billion by 2033 | Future Market Insights, Inc.
10 févr. 2023 06h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Hematology Diagnostics Market is expected to be worth $780.0 million in 2023 and $2.0 billion by 2033. During the forecast period, the market for...
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
18 janv. 2023 03h01 HE
|
Mainz BioMed NV
BERKELEY, US and MAINZ, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early...